Aiforia - Medical Image Analysis Software

In my own vision, talks are probably being held, considering the share price has been stuck in a deep rut and insiders haven’t made any share purchases even though they were fine buying at higher prices. Personally, I’d settle for some solid news about a profitable deal, even if the company isn’t being sold. Partnerships have only been announced sparsely now, and looking at industry developments around the world, things really ought to take off like a rocket soon if they’re ever going to take off at all.

6 Likes

The share price has taken a well-deserved 2/3 drop from a year ago, but does the valuation make any sense even now? Growth is nowhere to be seen, losses are deepening, and on top of that, it has become apparent this year that the revenue presumed to be recurring wasn’t actually recurring.

A €35m valuation for a company generating under €3m in revenue and burning around €10m of cash a year. Repeating last November’s assessment: the share price still has room to halve. It’s hard to see any future for the company other than a fire sale of what’s left or bankruptcy.

3 Likes

Matter of taste, but in my view, determining a company’s valuation isn’t quite that straightforward at the startup/VC end, when guessing future cash flows is extremely difficult.

7 Likes

True as well, but there are certain universal valuation principles. Generally, weak growth and heavy losses are not a good combination for a company’s value.

A company that has historically burned well over 50 million of investors’ money without showing any track record of growth is rarely tremendously valuable. Software companies generating revenue in the 2–3 million range are not valued in the tens of millions, unless the product has a massive international market, a rapid growth rate, and a convincing sales pipeline. Out of these three, Aiforia perhaps has the first one.

Even if Aiforia were to launch into rocket-like growth today (e.g., 60–100% per year), it would still need an additional 10–20 million in funding before operations turn profitable, meaning significant dilution is on the horizon even in a best-case scenario.

There is always, of course, the chance of a Mobidiag-style lottery win, where the strategic value to a buyer is independent of the company’s financial figures and the valuation could be anything.

6 Likes